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HEPATOCELLULAR carcinoma (HCC) is a major cause of morbidity and mortality worldwide, and HCC is the fifth most common cancer in males and the seventh most common cancer in females 1 . HCC is characterized by rapid development, early metastasis, poor prognosis and short survival time 2 . Traditional surgical therapies, including radiotherapy, chemotherapy, and a combination of traditional Chinese medicine and synthetic drugs, do not significantly improve the prognosis mainly because of the late presentation of large tumours; also only 10-20% of the carcinomas can be removed surgically. Even though clinical trials reported a statistically relevant increase in mean survival time, this survival comes about through the attenuation of disease progression but, ultimately does not represent a solution that leads to disease remission, which would be desirable. Following the development of genetics-based therapies for a myriad of diseases, similar treatments have been suggested for HCC based on promising preliminary results.
IGF-II is a foetal growth protein produced by liver cells. It is an important pro-angiogenic factor that can directly promote angiogenesis, and a number of liver cancer cell lines secrete it through autocrine or paracrine mechanisms 3 . The human IGF-II gene is a complex transcription unit containing four different promoters (P1-P4) 4 . In hepatocellular carcinoma (HCC) and in cell lines expressing IGF-II, P3 is the most active promoter 5 . P3 is also the major promoter in liver tumour tissues and in IGF-II-expressing cell lines. It is related to angiogenesis and indirectly promotes the formation of liver cancer blood vessels, thereby contributing to tumour development and invasion 6 . Deoxyribozymes (DNAzymes or DRzs) are synthetic, single-stranded catalytic DNA that can be engineered to bind by Watson-Crick base pairing to complementary sequences in a target messenger RNA (mRNA); DRzs can then cleave it at predetermined phosphodiester linkages. One of the most important properties of DNAzymes is currently also one of the most actively-researched topics 6 . The 10-23 DRz has been proposed as a general model for DRzs 7 . This DRz has been widely shown (both in vitro or in vivo) to inhibit the expression of its target genes and its dependent genes 7, 8 . Moreover, DRzs are able to attenuate the progression of a variety of pathologies in animal models, and they show significant potential as therapeutic tools 8 . They can also block the development of diverse pathologies in animal models and have potential utilities as therapeutic tools.
This study is a continuation of our previous research that showed that the previously designed IGF-IIP3-DNAzyme (IGF-II-DRz1) could inhibit cell proliferation and invasion and the motility and migration of SMMC-7721 cells in vitro 3, 4 . However, it is unclear whether IGF-IIP3-DRz1 displays any therapeutic effects on HCC growth in intact organisms. Consequently, we tested whether IGF-IIP3-DRz1 was able to reduce IGF-II levels to such an extent that tumour growth was attenuated in a mouse model of human hepatocarcinoma. The results from the current study might be used to optimize DRzbased therapeutics for HCC and might lead to subsequent phase I clinical testing.
The IGF-IIP3-DNAzyme (DRz1) 4 was designed as previously described by Dass et al. 9 . Briefly, a region of 10-23 DRz was made by incorporating two 8 bp arms complementary to the target gene into each side of the catalytic motif. As a control, an inactive, sequenceinverted DNAzyme (DRz1 inv ) was designed based on the flipped sequence of DRz1. Both DNAzymes were synthesized by Shanghai Sangon Biotechnology Co. Ltd (Shanghai, China). The sequences of human IGF-IIP3 mRNA templates and the corresponding DNAzymes were designed as follows (arrow indicates the cleavage point):
Template-1: 5′ AGACACCAA↓UGGGAAUC 3′ DNAzyme 1 (DRz1): 5′ GATTCCCAGGCTAGCTAC-AACGATGGTGTCT 3′ Inactive sequence: Inverted DNAzyme (DRz1 inv ): 5′ TCTGTGGTAGCA-ACATCGATCGGACCCTTAG 3′
In this study, the SMMC-7721 cell line was used as an HCC source and was purchased from the Cell Bank and Type Culture Collection of the Chinese Academy of Sciences (Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China). The cells were maintained and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (FBS; Gibco/Life Technologies, Grand Island, NY, USA), 100 IU/ml penicillin, 100 IU/ml streptomycin and 2 mmol/l L-glutamine in a humidified atmosphere (5% CO 2 , 37°C). The cells in the suspensions were counted using a Cedex analyzer (Innovatis AG, Bielefeld, Germany).
Twenty-four healthy male nude mice (weight 18-20 g, 4-5 weeks-old) were obtained from the Beijing Laboratory Animal Centre (Chinese Academy of Sciences, Beijing, China. The mice were housed in a pathogen-free laboratory animal centre, maintained at ~22°C under a 12 h dark/light cycle and given food and water ad libitum. All experimental procedures that involved lab animals were performed according to the Institutional Animal Care and Use Committee's guidelines of Beihua University and were approved by the Experimental Animal Ethics Committee of Beihua University.
Briefly, 5 × 10 6 SMMC-7721 cells were suspended in 200 μl PBS and were inoculated subcutaneously into nude mice to set up the SMMC-7721 tumour-bearing animal model. After 4 weeks, when the tumours were approximately 4-5 mm in diameter (measured with a caliper), the mice were randomly divided into three groups of eight mice each: (i) a sham-treated control group, (ii) an inactive DRz group (DRz1 inv ) and (iii) a DRz1 group. Each mouse received daily, multipoint intratumoural injections with 10 μg DRz1 or DRz1 inv dissolved in 10 μl PBS. The control group received an equal volume of PBS. The tumour sizes were monitored every two days, and the tumour volume was calculated using the following formula: V = (length × width 2 )/2. After 14 days of daily injections, the mice in each group were sacrificed by decapitation, and the tumours were excised. Postmortem, the body weight of the mice, the excised tumour dimensions and the excised tumour wet weight were determined. Subsequently, the tumours were either flash frozen in liquid nitrogen or were fixed in 4% paraformaldehyde overnight, followed by cryoprotection in 25% sucrose for several days. The cryoprotected tumours were then washed with 0.1% PBS prior to being embedded in optimal cutting temperature (OCT) compound; the tumours were then sectioned into 8 micron sections. For analysis of the mRNA and protein expression levels in tumours, the OCT compound-embedded tumour sections were scraped from glass slides containing individual tumours; the scraped tumours were pooled according to the treatment group to obtain sufficient tissue for further analysis. The tissues were frozen in liquid nitrogen and were stored at -80°C until analysis.
The IGF-IIP3 and VEGF mRNA expression levels in the excised tumour tissue of the various treatment groups were quantified by real-time PCR. The housekeeping gene β-actin was used as a control. Human IGF-II, VEGF and β-actin PCR primers were designed using Primer Express software (Perkin-Elmer Biosystems, USA) based on their published sequences (Table 1 ). The total RNA was isolated from the frozen tumour tissue with TRIzol Reagent (Invitrogen, Rockville, MD, USA) according to the manufacturer's instructions. To avoid DNA contamination, the total RNA was treated with RNase-free DNase I (Takara, Kyoto, Japan) for 60 min at 37°C and was extracted once more with the TRIzol reagent. The RNA purity was determined from the 260/280 nm absorbance ratio, and the RNA integrity was assessed by determining the intensity of the 28S and 18S rRNA bands after formaldehyde agarose gel electrophoresis. The total RNA (2 μg) was subjected to reverse transcription using a RevertAid TM First-Strand cDNA Synthesis Kit (Fermentas Inc., Glen Burnie, MD, USA) with a random hexamer primer; cDNA solution (2 μl) was used for real-time PCR. The genes were amplified in a 25 μl reaction volume using SYBR Universal PCR Master Mix (Tiangen Biotech, Beijing, China) on a MiniOpticon™ Real-time PCR System (Bio-Rad, Hercules, CA, USA). The temperature profile consisted of an initial denaturation step at 95°C for 5 min, followed by 40 cycles of 95°C for 10 sec, 58°C for 15 sec and 72°C for 10 sec before being subjected to a melting curve analysis 10 . The specificity of the amplified products was evaluated via agarose gel electrophoresis and was further verified with automated cycle sequencing. To ensure consistency in the threshold cycle (Ct) values, triplicate reactions were performed, and the mean Ct values were used for calculating the relative expression levels. The Ct values were analysed as described previously by Zhou et al. 11 , and the normalized Ct values for each gene were subjected to Student's t-test with a two-tailed distribution to determine the statistical significance (95% confidence interval). The final measurements were carried out in triplicate, and the mean values were calculated. For standardization purposes, β-actin was used as an internal control in each sample.
The IGF-IIP3, VEGF, caspase-3 and caspase-9 protein expression levels from the frozen tumour tissues of various treatment groups were quantified by western blot. The tumour tissues were cut into small pieces, weighed and washed twice with pre-cooled PBS. The tumour tissue was treated with RIPA buffer (50 mmol/l Tris (pH 8.0), 150 mmol/l NaCl, 0.1% SDS, 1% NP40 and 0.5% sodium deoxycholate) containing protease inhibitors (1% cocktail and 1 mmol/l PMSF). The tumour tissue was homogenized with a low-speed homogenizer for 30 sec after each time interval of 1 min in an ice bath until lysis was complete. The lysate was centrifuged at 14,000 g with an ice-cold centrifuge for 15 min. The supernatant was immediately transferred and saved at -80°C until analysis. The total protein extracts were separated on a 15% SDS-PAGE and were transferred to PVDF membranes. The membranes were blocked with tris-buffered saline containing 0.1% Tween 20 (pH 7.6, [TBS-T]) for 1 h at room temperature. Subsequently, the PVDF membranes were immunoblotted overnight at 4°C with the first antibody (see below) solution (1 : 1000). After washing twice with TBS-T, the membrane was incubated with an HRP-labelled secondary goat anti-mouse IgG 2a -B antibody (SC-2073) for 1 h at room temperature and was washed three times with TBS-T. The final detection was performed with enhanced chemiluminescence (ECL) western blotting reagents (GE Healthcare, Piscataway, NJ, USA), and the membranes were exposed to the LumiFilm Chemiluminescent Detection Film (Roche Applied Science, Rotkreuz, Switzerland). The loading differences were normalized by using a monoclonal β-actin antibody against the housekeeping control β-actin. The primary antibodies used in this study included the following: anti-IGF-IIP3 (SC-7435), anticaspase-3 (SC-7272), VEGF (SC-7269) and anti-β-actin (SC-130301) and were all acquired from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The tumours were immersed in 4% paraformaldehyde for 4 h and were transferred to 70% ethanol. Individual lobes of tumour biopsy material were placed in processing cassettes, dehydrated through a serial alcohol gradient, and embedded in paraffin wax blocks. Before immunostaining, 5 μm-thick lung tissue sections were dewaxed in xylene, rehydrated with decreasing concentrations of ethanol and washed in PBS. The cells were then stained with hematoxylin and eosin (H&E). After staining, the sections were dehydrated through increasing concentrations of ethanol and xylene 12 . The measurements were performed in triplicate, and the results expressed as the means ± SD. One-way analysis of variance (ANOVA) or Student's t-tests were carried out using statistical analysis software (SPSS, Chicago, IL, USA). The tumour growth over time was analysed among the three groups by two-way ANOVA using Graphpad Prism version 4.0b software (Graphpad Software, Inc., La Jolla, CA, USA). The values of P < 0.05 were considered to be statistically significant.
DRz1 was able to attenuate the IGF-IIP3 mRNA and protein expression concomitantly by nearly 50% in SMMC-7721 cells 4 . This downregulation of IGF-IIP3 expression was associated with increased caspase-3 and caspase-9 activity and inhibited the cell proliferation and increased apoptosis. We evaluated the effectiveness of DRz1 in human hepatocarcinoma tumours grafted subcutaneously onto nude mice. The grafted tumours were treated daily with 1 μg/μl (10 μg/10 μl PBS) DRz1, DRz1 inv or 10 μl PBS alone for 14 days via multipoint intra-tumoural injections.
Subjectively, none of the animals showed any signs of distress or disruption to their feeding or sleep cycles. Furthermore, the results in Figure 1 show no significant differences in body weight development; therefore, the discomfort or disruption of bodily homeostasis due to tumour growth may have been minimal. During excision, the capillaries were observed visually in the vicinity of the tumour grafts, and several sprouts penetrated the excised tumours (Figure 2 b) .
As shown in Figure 2 , compared to the sham-treated control group, DRz1 treatment attenuated the tumour volume and weight after 14 days of treatment by a factor of 1.40 and 1.41 respectively (Figure 2 a) . Furthermore, the appropriateness of the chosen negative control, DRz1 inv , is reflected in the fact that no significant differences were observed between the sham-treated and DRz1 inv groups. Our results show that IGF-IIP3-DRz1 could inhibit the IGF-IIP3 mRNA and protein levels in tumours and that DRz1 could inhibit tumour growth without obvious adverse effects. This anti-tumour growth effect was related to the inhibition of IGF-II expression by DRz1. Similar anti-tumour growth effects were reported in DZ2, a DNAzyme that targets aurora kinase A, induces apoptosis and inhibits tumour growth in human prostate cancer 7 . To evaluate to what extent DRz1 was able to attenuate the effects of IGF-II expression in the solid tumour mass, the IGF-IIP3 mRNA and protein levels were determined. Our results show that the mRNA levels were effectively attenuated by approximately 1.49-66.9 ± 5.7% of shamtreated control within cells from tumour cross-sections treated consecutively with 10 μg DRz1 (Figure 3 a) . These results show the basic capacity of DRz1 to attenuate IGF-IIP3 gene expression. Equal protein expression was attenuated by approximately 1.47-68 ± 4.9% of the control (Figure 3 b) . Furthermore, no additional effect was effectively observed at concentrations above 10 μg DRz1, as the mRNA and protein expression levels levelled off to a plateau. The sequence-inverted control DRz did not affect the IGF-IIP3 expression levels. It is likely that, at least partially, the degradation of the DRzs by tumour-endogenous exonucleases abolishes the knockdown of IGF-IIP3 expression and leads to the restoration of IGF-IIP3 expression over time. The 10-23 DNAzymes targeting GATA-3 mRNA have recently been developed, and their anti-asthmatic effect in mouse models has been successfully demonstrated 13 ; DNAzymes have been widely applied as a new interference strategy in the treatment of cancer 14 . Vascular endothelial growth factor (VEGF) is one of the hallmarks of malignant tumour formation, invasiveness and growth, and we previously showed that DRz1 was able to inhibit VEGF in cultures of SMMC-7721 3 . Therefore, we assayed the expression of VEGF in response to treatment with DRz1 via real-time PCR and Western blotting to evaluate the capacity of DRz1 to inhibit VEGF in the tumour and paratumour tissues. The results in Figure 4 show that DRz1 was able to significantly downregulate the expression of VEGF in both the tumour and paratumoural tissues, whereas no difference was observed in the sequence-inverted and sham-treated controls. The magnitude of down-regulation was equally large in the tumour (approximately 1.53-65.4 ± 7.2%) and in the surrounding tissues (approximately 1.47-67.9 ± 4.7%). Immunohistochemical techniques have been used to evaluate the expression of VEGF in tumours.
VEGF is a major regulator of the blood vessel growth that is required for tissue differentiation and function. Remarkably, the aberrant expression of VEGF in tumours and in paratumours is a hallmark of malignant tumour development. Previous findings indicate that DRz1 inhibits Figure 3 . Effect of the anti-IGF-II DNAzyme DRz1 on insulin-like growth factor IIP3 (IGF-IIP3) expression in xenografted hepatocarcinoma tumours in nude mice. a, IGF-IIP3 mRNA expression after 14 days of treatment; top: representative blot. Data shown are the means ± SD of normalized, relative IGF-IIP3 mRNA levels (n ≥ 3). *Denotes a significant difference from the sham-treated control (P < 0.05). b, Representative western blots of IGF-IIP3 protein levels. Protein expression was quantified via densitometry and was compared with the sham-treated control. The maximal grey value (black) was set to 1, and all other results are expressed relative to this value (n ≥ 3). All gels and blots were run under the same conditions. DRz1 inv : Inactive, inverted DNAzyme sequence. Figure 4 . Effect of the anti-IGF-II DNAzyme DRz1 (10 µg/µL) on vascular endothelial growth factor (VEGF) expression in xenografted hepatocarcinoma tumours in nude mice. a, VEGF mRNA expression after 14 days of treatment; top: representative blot. Data shown are the means ± SD of normalized, relative VEGF mRNA levels (n ≥ 3). *Denotes a significant difference from the sham-treated control (P < 0.05). b, Representative Western blots of VEGF protein levels. Protein expression was quantified via densitometry and was compared with the sham-treated control. The maximal grey value (black) was set to 1, and all other results are expressed relative to this value (n ≥ 3). All gels and blots were run under the same conditions. DRz1 inv : Inactive, inverted DNAzyme sequence; IGF-II: Insulin-like growth factor II. c, Immunohistochemical assay of VEGF in the tumour tissues.
cell migration in SMMC-7721 cells 3 , and DRzs markedly decrease VEGF expression. In addition, DRzs significantly suppress the expression of MMP-9, but not of MMP-2, in SMMC-7721 cells. MMPs are proteolytic enzymes that degrade the extracellular matrix and the basement membranes of cells, and MMP-2 and MMP-9 are the most vital enzymes for degradation 15 . Therefore, they are considered to have major significance for tumour invasion and metastasis. Our studies have previously demonstrated that DRzs could inhibit the invasion and motility of SMMC-7721 cells by a mechanism that involves the downregulation of MMP-9 and VEGF. In this study, our results show that DRz1 could reduce the expression of VEGF in tumour and paratumour tissues ( Figure 3 ) and could inhibit migration in vivo.
To evaluate the extent that DRz1 was able to activate the caspase-3/9 pathway in the solid tumour tissue, the procaspase-3 and 9 expression levels were determined in the tumour tissue. As shown in Figure 5 , compared to the expression levels, the control group (the PBS injection group), the procaspase-3 and procaspase-9 expression levels decreased significantly in the DRz1-treated group, whereas inactive DRz1 showed no effect on the expression levels of procaspase-3 and procaspase-9.
Our results generally demonstrate that DRz1 could significantly inhibit the expression of IGF-IIP3 and the associated tumour-promoting proteins, and DRz1 could retard the growth of hepatocarcinoma tumours in vivo. These findings provide proof-of-principle results and are the basis for the further development of this DNAzyme as a novel therapeutic intervention for liver cancer treatment, although further development is required.
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